Filip Janku is Chief Medical Officer at Monte Rosa Therapeutics, Inc. (GLUE). They have made 2 open-market trades across 1 company since 2026, most recently 2026-06-30.
CIK 0001862930
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GLUE | 60,612 | $591K |
Shares reported on the most recent Form 4, priced at the 2026-07-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GLUE | SELL · 10b5-1 | 2026-06-30 | 2026-07-01 | $24.50 | $132K | -0.4% | -29.8% | -50.1% |
| GLUE | SELL · 10b5-1 | 2026-06-29 | 2026-06-30 | $22.95 | $138K | -9.8% | -7.0% | -51.9% |
| GLUE | SELL · 10b5-1 | 2026-06-23 | 2026-06-25 | $21.08 | $882K | +9.2% | +2.5% | -46.0% |
| GLUE | SELL | 2026-02-23 | 2026-02-24 | $19.50 | $179K | -7.3% | -18.4% | -0.1% |
| GLUE | SELL | 2026-01-05 | 2026-01-05 | $15.17 | $48K | +69.9% | +37.8% | +19.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.